Induced Pluripotent Stem Cell (iPS Cells) - Content Archive

Kenai Therapeutics Emerges with $82M to Advance Its Allogeneic, iPSC-Derived Therapy for Parkinson’s Disease

March 14, 2024 By Cade Hildreth, Founder & President Leave a Comment

Kenai Therapeutics has emerged from stealth mode with $82M to invest in its allogeneic iPSC-derived cell therapeutic for Parkinson’s disease (PD).

Proceeds to be used to complete clinical proof-of-concept trial for Kenai’s lead candidate, RNDP-001, for the treatment of Parkinson’s disease.

Financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures.

[Read more…]

Revolutionary Elephant iPSC Milestone Reached in Colossal’s Woolly Mammoth Project

March 11, 2024 By Cade Hildreth, Founder & President Leave a Comment

Colossal scientists achieve global first; technology promises seminal advancements for engineering Woolly Mammoth phenotypes in in vitro cellular models, developmental biology, and attaining balance between senescence and cell growth

DALLAS, Texas, March 06, 2024 – Colossal Biosciences, the world’s first de-extinction company, announced that their Woolly Mammoth team has achieved a global-first iPSC (induced pluripotent stem cells) breakthrough. This milestone advancement was one of the primary early goals of the mammoth project, and supports the feasibility of future multiplex ex utero mammoth gestation. [Read more…]

First Patient Treated in Phase 2 GvHD Trial

March 5, 2024 By Cade Hildreth, Founder & President Leave a Comment

Melbourne, Australia; 5 March 2024 – Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD). [Read more…]

Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells

February 22, 2024 By Cade Hildreth, Founder & President Leave a Comment

The addition of ES cells and iPSCs will enhance Charles River’s portfolio of powerful research tools supporting acceleration of therapeutic development.

WILMINGTON, Mass., February 20, 2024 – Charles River Laboratories International, Inc. (NYSE: CRL) announced that it has entered into an agreement with Pluristyx Inc., a leading provider of tools, technologies, and services for the development of cell therapies. The collaboration provides Charles River with broad access to highly characterized and unique stem cell lines, including high-quality embryonic stem (ES) cells and induced pluripotent stem cells (iPSCs) as research tools to support development of new therapeutics. [Read more…]

Induced Pluripotent Stem Cell (iPS Cell) Applications in 2024

February 10, 2024 By Cade Hildreth, Founder & President Leave a Comment

Since the discovery of induced pluripotent stem cell (iPSC) technology 18 years ago, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated. [Read more…]